Oct 1 (Reuters) - Nasdaq said on Thursday that vaccine maker Moderna will replace Warner Bros. Discovery on the Nasdaq 100 ...

Moderna (MRNA) stock rose after confirming Nasdaq-100 inclusion, even as Citi downgrades the stock on valuation concerns.

Warner Bros. Discovery exits the Nasdaq 100 and S&P 500 next week as its $81B Paramount Skydance merger closes. Moderna and ...

That could leave the stock due for a pullback according to Citi, whose Street-low target of $80 would suggest a nearly 60% ...

Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.

Citi analyst says Moderna stock could crash as much as 60% from here. Here’s why he issued a bearish note on MRNA shares ...

A coveted Presidential Symposium slot at Europe's top oncology congress just sent Moderna shares flying 9%, but the actual ...

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is drawing attention Wednesday after Citigroup downgraded the biotech ...

Moderna stock MRNA fell nearly 6% in premarket trading on Wednesday after Citi downgraded the biotech company to ‘Sell’ from ...

Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at ...

Moderna stock has rallied more than 200% since August, following positive Phase 3 trial results for a melanoma vaccine.